The incidence of sudden cardiac arrest recurrence following defibrillator implantation is high across all patient groups, regardless of aetiology, and sustained ventricular tachycardia as the indication for device implantation predicts a higher incidence.
Abstract
Introduction. Randomised clinical trials have demonstrated the indispensable role of implantable cardioverter defibrillators in reducing mortality among patients at high risk of sudden cardiac death. This study aimed to assess the incidence and predictors of cardiac arrest recurrence in such patients. Material and Methods. This retrospective study included 240 patients who underwent defibrillator implantation for secondary prevention at the Institute for Cardiovascular Diseases of Vojvodina between 2008 and 2020. The cumulative incidence of recurrence was determined using Kaplan-Meier curves, while Cox regression was used to identify predictors of sudden cardiac arrest recurrence. Results. The median follow-up was 4.46 years, and recurrence of sudden cardiac arrest occurred in 60% (n=144) of patients. Sustained ventricular tachycardia as the indication for implantation was shown to be an independent predictor of recurrence. These patients also had a significantly higher number of hospitalisations during follow-up. Patients diagnosed with channelopathy or arrhythmogenic right ventricular dysplasia had a significantly higher number of hospitalisations than those diagnosed with ischaemic or non-ischaemic cardiomyopathy. Conclusion. The incidence of sudden cardiac arrest recurrence following defibrillator implantation is high across all patient groups, regardless of aetiology. Sustained ventricular tachycardia as the indication for device implantation predicts a higher incidence of cardiac arrest recurrence.
INTRODUCTION
In patients who survive out-of-hospital cardiac arrest (OHCA), guidelines for implantation of an implantable cardioverter-defibrillator (ICD) are not unequivocal.
METHODS
Patients resuscitated from OHCA of cardiac cause, without a reversible cause and an expected survival >1 year were identified (year 20...
M. Winther-Jensen, B. T. Philbert, M. L. Laursen et al.· Scandinavian Cardiovascular...· 0 citations
Implantable cardioverter-defibrillators (ICDs) and cardiac resynchronization therapy defibrillators (CRT-Ds) are effective in preventing sudden cardiac death. However, inappropriate shocks (Inap-S) may impair quality of life and have been associated with adverse clinical outcomes. This study evaluated the incidence...
J. Pereira, S. Andraz, Lucas Hamann et al.· Cardiology Plus· 0 citations
Background: Implantable cardioverter defibrillators (ICDs) are essential for the primary prevention of sudden cardiac death in heart failure (HF); however, appropriate shocks increase mortality and impair quality of life. The electrical risk score (ERS) is an electrocardiographic (ECG)-based composite index with proven...
P. Aladağ, I. Erbay, N. E. Güdül et al.· Journal of Clinical Medicine· 0 citations
In this analysis including a large cohort of post-myocardial infarction patients with reduced LVEF, the estimated mortality reduction associated with primary prevention ICD implantation progressively decreased over time.
Alireza Sepehri Shamloo, T. Chiba, J. G. Tijssen et al.· European Heart Journal· 0 citations
Aim.
To identify clinical and instrumental factors associated with clinical outcomes in patients with implanted implantable cardioverterdefibrillators (ICD) / cardiac resynchronization therapy defibrillators (CRTD).
Material and methods.
A singlecenter retrospective registry included clinical and instrumental...
K. N. Kozaeva, E. Rimskaya, G. Tarasovskiy et al.· Journal of Arrhythmology· 0 citations
In this international multicenter study, the largest to date, including >3300 consecutive patients with HCM and ICDs, device therapy terminated potentially lethal ventricular tachyarrhythmias in 1 of 6 patients, with low HCM-related mortality rates for patients with ICDs.
E. Rowin, B. J. Maron, K. Siontis et al.· Circulation· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.